The global market for Oral Hypoglycemic Agents (OHAs) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Oral hypoglycemic agents (OHAs) are a group of drugs used to help reduce the amount of sugar present in the blood. They are not insulin, but they stimulate the pancreas to produce insulin.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oral Hypoglycemic Agents (OHAs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Hypoglycemic Agents (OHAs).

The Oral Hypoglycemic Agents (OHAs) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oral Hypoglycemic Agents (OHAs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Oral Hypoglycemic Agents (OHAs) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Oral Hypoglycemic Agents (OHAs) Market Report

Report Metric	Details
Report Name	Oral Hypoglycemic Agents (OHAs) Market
CAGR	5%
Segment by Type	Sulfonylureas Metformin Thiazolidinediones Alpha-Glucosidase Inhibitors
Segment by Application	Type 2 Diabetes Mellitus Type 1 Diabetes Mellitus
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Pfizer, GlaxoSmithKline, Bayer, Bristol-Myers Squibb, Novonordisk, Sanofi-Aventis, Servier, Huadong Medicine, Wanbang Biopharmaceuticals, Double-Crane Pharmaceutical, Guangzhou Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oral Hypoglycemic Agents (OHAs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oral Hypoglycemic Agents (OHAs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Oral Hypoglycemic Agents (OHAs) Market report?

Ans: The main players in the Oral Hypoglycemic Agents (OHAs) Market are Pfizer, GlaxoSmithKline, Bayer, Bristol-Myers Squibb, Novonordisk, Sanofi-Aventis, Servier, Huadong Medicine, Wanbang Biopharmaceuticals, Double-Crane Pharmaceutical, Guangzhou Pharmaceutical

What are the Application segmentation covered in the Oral Hypoglycemic Agents (OHAs) Market report?

Ans: The Applications covered in the Oral Hypoglycemic Agents (OHAs) Market report are Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus

What are the Type segmentation covered in the Oral Hypoglycemic Agents (OHAs) Market report?

Ans: The Types covered in the Oral Hypoglycemic Agents (OHAs) Market report are Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors

1 Oral Hypoglycemic Agents (OHAs) Market Overview

1.1 Product Definition

1.2 Oral Hypoglycemic Agents (OHAs) by Type

1.2.1 Global Oral Hypoglycemic Agents (OHAs) Market Value Comparison by Type (2024 VS 2031)

1.2.2 Sulfonylureas

1.2.3 Metformin

1.2.4 Thiazolidinediones

1.2.5 Alpha-Glucosidase Inhibitors

1.3 Oral Hypoglycemic Agents (OHAs) by Application

1.3.1 Global Oral Hypoglycemic Agents (OHAs) Market Value by Application (2024 VS 2031)

1.3.2 Type 2 Diabetes Mellitus

1.3.3 Type 1 Diabetes Mellitus

1.4 Global Oral Hypoglycemic Agents (OHAs) Market Size Estimates and Forecasts

1.4.1 Global Oral Hypoglycemic Agents (OHAs) Revenue 2020-2031

1.4.2 Global Oral Hypoglycemic Agents (OHAs) Sales 2020-2031

1.4.3 Global Oral Hypoglycemic Agents (OHAs) Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Oral Hypoglycemic Agents (OHAs) Market Competition by Manufacturers

2.1 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Manufacturers (2020-2025)

2.2 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Oral Hypoglycemic Agents (OHAs) Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Oral Hypoglycemic Agents (OHAs), Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Oral Hypoglycemic Agents (OHAs), Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Oral Hypoglycemic Agents (OHAs), Product Type & Application

2.7 Global Key Manufacturers of Oral Hypoglycemic Agents (OHAs), Date of Enter into This Industry

2.8 Global Oral Hypoglycemic Agents (OHAs) Market Competitive Situation and Trends

2.8.1 Global Oral Hypoglycemic Agents (OHAs) Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Oral Hypoglycemic Agents (OHAs) Players Market Share by Revenue

2.8.3 Global Oral Hypoglycemic Agents (OHAs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Oral Hypoglycemic Agents (OHAs) Market Scenario by Region

3.1 Global Oral Hypoglycemic Agents (OHAs) Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Region: 2020-2031

3.2.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Region: 2020-2025

3.2.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Region: 2026-2031

3.3 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region: 2020-2031

3.3.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region: 2020-2025

3.3.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region: 2026-2031

3.4 North America Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country

3.4.1 North America Oral Hypoglycemic Agents (OHAs) Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2020-2031)

3.4.3 North America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country

3.5.1 Europe Oral Hypoglycemic Agents (OHAs) Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2020-2031)

3.5.3 Europe Oral Hypoglycemic Agents (OHAs) Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Region

3.6.1 Asia Pacific Oral Hypoglycemic Agents (OHAs) Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Region (2020-2031)

3.6.3 Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country

3.7.1 Latin America Oral Hypoglycemic Agents (OHAs) Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Oral Hypoglycemic Agents (OHAs) Sales by Country (2020-2031)

3.7.3 Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country

3.8.1 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Country (2020-2031)

3.8.3 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2020-2031)

4.1.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2020-2025)

4.1.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2026-2031)

4.1.3 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2020-2031)

4.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2020-2031)

4.2.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2020-2025)

4.2.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2026-2031)

4.2.3 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2020-2031)

4.3 Global Oral Hypoglycemic Agents (OHAs) Price by Type (2020-2031)

5 Segment by Application

5.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2020-2031)

5.1.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2020-2025)

5.1.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2026-2031)

5.1.3 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2020-2031)

5.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2020-2031)

5.2.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2020-2025)

5.2.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2026-2031)

5.2.3 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2020-2031)

5.3 Global Oral Hypoglycemic Agents (OHAs) Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Pfizer

6.1.1 Pfizer Company Information

6.1.2 Pfizer Description and Business Overview

6.1.3 Pfizer Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Pfizer Oral Hypoglycemic Agents (OHAs) Product Portfolio

6.1.5 Pfizer Recent Developments/Updates

6.2 GlaxoSmithKline

6.2.1 GlaxoSmithKline Company Information

6.2.2 GlaxoSmithKline Description and Business Overview

6.2.3 GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2020-2025)

6.2.4 GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Product Portfolio

6.2.5 GlaxoSmithKline Recent Developments/Updates

6.3 Bayer

6.3.1 Bayer Company Information

6.3.2 Bayer Description and Business Overview

6.3.3 Bayer Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Bayer Oral Hypoglycemic Agents (OHAs) Product Portfolio

6.3.5 Bayer Recent Developments/Updates

6.4 Bristol-Myers Squibb

6.4.1 Bristol-Myers Squibb Company Information

6.4.2 Bristol-Myers Squibb Description and Business Overview

6.4.3 Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Product Portfolio

6.4.5 Bristol-Myers Squibb Recent Developments/Updates

6.5 Novonordisk

6.5.1 Novonordisk Company Information

6.5.2 Novonordisk Description and Business Overview

6.5.3 Novonordisk Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Novonordisk Oral Hypoglycemic Agents (OHAs) Product Portfolio

6.5.5 Novonordisk Recent Developments/Updates

6.6 Sanofi-Aventis

6.6.1 Sanofi-Aventis Company Information

6.6.2 Sanofi-Aventis Description and Business Overview

6.6.3 Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Product Portfolio

6.6.5 Sanofi-Aventis Recent Developments/Updates

6.7 Servier

6.7.1 Servier Company Information

6.7.2 Servier Description and Business Overview

6.7.3 Servier Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Servier Oral Hypoglycemic Agents (OHAs) Product Portfolio

6.7.5 Servier Recent Developments/Updates

6.8 Huadong Medicine

6.8.1 Huadong Medicine Company Information

6.8.2 Huadong Medicine Description and Business Overview

6.8.3 Huadong Medicine Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Huadong Medicine Oral Hypoglycemic Agents (OHAs) Product Portfolio

6.8.5 Huadong Medicine Recent Developments/Updates

6.9 Wanbang Biopharmaceuticals

6.9.1 Wanbang Biopharmaceuticals Company Information

6.9.2 Wanbang Biopharmaceuticals Description and Business Overview

6.9.3 Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Product Portfolio

6.9.5 Wanbang Biopharmaceuticals Recent Developments/Updates

6.10 Double-Crane Pharmaceutical

6.10.1 Double-Crane Pharmaceutical Company Information

6.10.2 Double-Crane Pharmaceutical Description and Business Overview

6.10.3 Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Portfolio

6.10.5 Double-Crane Pharmaceutical Recent Developments/Updates

6.11 Guangzhou Pharmaceutical

6.11.1 Guangzhou Pharmaceutical Company Information

6.11.2 Guangzhou Pharmaceutical Description and Business Overview

6.11.3 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Portfolio

6.11.5 Guangzhou Pharmaceutical Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Oral Hypoglycemic Agents (OHAs) Industry Chain Analysis

7.2 Oral Hypoglycemic Agents (OHAs) Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Oral Hypoglycemic Agents (OHAs) Production Mode & Process Analysis

7.4 Oral Hypoglycemic Agents (OHAs) Sales and Marketing

7.4.1 Oral Hypoglycemic Agents (OHAs) Sales Channels

7.4.2 Oral Hypoglycemic Agents (OHAs) Distributors

7.5 Oral Hypoglycemic Agents (OHAs) Customer Analysis

8 Oral Hypoglycemic Agents (OHAs) Market Dynamics

8.1 Oral Hypoglycemic Agents (OHAs) Industry Trends

8.2 Oral Hypoglycemic Agents (OHAs) Market Drivers

8.3 Oral Hypoglycemic Agents (OHAs) Market Challenges

8.4 Oral Hypoglycemic Agents (OHAs) Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Wanbang Biopharmaceuticals

Double-Crane Pharmaceutical

Guangzhou Pharmaceutical

List of Tables

Table 1. Global Oral Hypoglycemic Agents (OHAs) Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Oral Hypoglycemic Agents (OHAs) Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Oral Hypoglycemic Agents (OHAs) Market Competitive Situation by Manufacturers in 2024

Table 4. Global Oral Hypoglycemic Agents (OHAs) Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Oral Hypoglycemic Agents (OHAs) Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Oral Hypoglycemic Agents (OHAs) Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Oral Hypoglycemic Agents (OHAs) Average Price (USD/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Oral Hypoglycemic Agents (OHAs), Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Oral Hypoglycemic Agents (OHAs), Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Oral Hypoglycemic Agents (OHAs), Product Type & Application

Table 12. Global Key Manufacturers of Oral Hypoglycemic Agents (OHAs), Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Oral Hypoglycemic Agents (OHAs) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Hypoglycemic Agents (OHAs) as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Oral Hypoglycemic Agents (OHAs) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Oral Hypoglycemic Agents (OHAs) Sales by Region (2020-2025) & (K Units)

Table 18. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region (2020-2025)

Table 19. Global Oral Hypoglycemic Agents (OHAs) Sales by Region (2026-2031) & (K Units)

Table 20. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region (2026-2031)

Table 21. Global Oral Hypoglycemic Agents (OHAs) Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region (2020-2025)

Table 23. Global Oral Hypoglycemic Agents (OHAs) Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region (2026-2031)

Table 25. North America Oral Hypoglycemic Agents (OHAs) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2020-2025) & (K Units)

Table 27. North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2026-2031) & (K Units)

Table 28. North America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Oral Hypoglycemic Agents (OHAs) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2020-2025) & (K Units)

Table 32. Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2026-2031) & (K Units)

Table 33. Europe Oral Hypoglycemic Agents (OHAs) Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Oral Hypoglycemic Agents (OHAs) Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Oral Hypoglycemic Agents (OHAs) Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Oral Hypoglycemic Agents (OHAs) Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Oral Hypoglycemic Agents (OHAs) Sales (K Units) by Type (2020-2025)

Table 51. Global Oral Hypoglycemic Agents (OHAs) Sales (K Units) by Type (2026-2031)

Table 52. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2020-2025)

Table 53. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2026-2031)

Table 54. Global Oral Hypoglycemic Agents (OHAs) Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Oral Hypoglycemic Agents (OHAs) Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2020-2025)

Table 57. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2026-2031)

Table 58. Global Oral Hypoglycemic Agents (OHAs) Price (USD/Unit) by Type (2020-2025)

Table 59. Global Oral Hypoglycemic Agents (OHAs) Price (USD/Unit) by Type (2026-2031)

Table 60. Global Oral Hypoglycemic Agents (OHAs) Sales (K Units) by Application (2020-2025)

Table 61. Global Oral Hypoglycemic Agents (OHAs) Sales (K Units) by Application (2026-2031)

Table 62. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2020-2025)

Table 63. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2026-2031)

Table 64. Global Oral Hypoglycemic Agents (OHAs) Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Oral Hypoglycemic Agents (OHAs) Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2020-2025)

Table 67. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2026-2031)

Table 68. Global Oral Hypoglycemic Agents (OHAs) Price (USD/Unit) by Application (2020-2025)

Table 69. Global Oral Hypoglycemic Agents (OHAs) Price (USD/Unit) by Application (2026-2031)

Table 70. Pfizer Company Information

Table 71. Pfizer Description and Business Overview

Table 72. Pfizer Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 73. Pfizer Oral Hypoglycemic Agents (OHAs) Product

Table 74. Pfizer Recent Developments/Updates

Table 75. GlaxoSmithKline Company Information

Table 76. GlaxoSmithKline Description and Business Overview

Table 77. GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 78. GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Product

Table 79. GlaxoSmithKline Recent Developments/Updates

Table 80. Bayer Company Information

Table 81. Bayer Description and Business Overview

Table 82. Bayer Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 83. Bayer Oral Hypoglycemic Agents (OHAs) Product

Table 84. Bayer Recent Developments/Updates

Table 85. Bristol-Myers Squibb Company Information

Table 86. Bristol-Myers Squibb Description and Business Overview

Table 87. Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 88. Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Product

Table 89. Bristol-Myers Squibb Recent Developments/Updates

Table 90. Novonordisk Company Information

Table 91. Novonordisk Description and Business Overview

Table 92. Novonordisk Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 93. Novonordisk Oral Hypoglycemic Agents (OHAs) Product

Table 94. Novonordisk Recent Developments/Updates

Table 95. Sanofi-Aventis Company Information

Table 96. Sanofi-Aventis Description and Business Overview

Table 97. Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 98. Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Product

Table 99. Sanofi-Aventis Recent Developments/Updates

Table 100. Servier Company Information

Table 101. Servier Description and Business Overview

Table 102. Servier Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 103. Servier Oral Hypoglycemic Agents (OHAs) Product

Table 104. Servier Recent Developments/Updates

Table 105. Huadong Medicine Company Information

Table 106. Huadong Medicine Description and Business Overview

Table 107. Huadong Medicine Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 108. Huadong Medicine Oral Hypoglycemic Agents (OHAs) Product

Table 109. Huadong Medicine Recent Developments/Updates

Table 110. Wanbang Biopharmaceuticals Company Information

Table 111. Wanbang Biopharmaceuticals Description and Business Overview

Table 112. Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 113. Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Product

Table 114. Wanbang Biopharmaceuticals Recent Developments/Updates

Table 115. Double-Crane Pharmaceutical Company Information

Table 116. Double-Crane Pharmaceutical Description and Business Overview

Table 117. Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 118. Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product

Table 119. Double-Crane Pharmaceutical Recent Developments/Updates

Table 120. Guangzhou Pharmaceutical Company Information

Table 121. Guangzhou Pharmaceutical Description and Business Overview

Table 122. Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 123. Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product

Table 124. Guangzhou Pharmaceutical Recent Developments/Updates

Table 125. Key Raw Materials Lists

Table 126. Raw Materials Key Suppliers Lists

Table 127. Oral Hypoglycemic Agents (OHAs) Distributors List

Table 128. Oral Hypoglycemic Agents (OHAs) Customers List

Table 129. Oral Hypoglycemic Agents (OHAs) Market Trends

Table 130. Oral Hypoglycemic Agents (OHAs) Market Drivers

Table 131. Oral Hypoglycemic Agents (OHAs) Market Challenges

Table 132. Oral Hypoglycemic Agents (OHAs) Market Restraints

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Product Picture of Oral Hypoglycemic Agents (OHAs)

Figure 2. Global Oral Hypoglycemic Agents (OHAs) Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Oral Hypoglycemic Agents (OHAs) Market Share by Type: 2024 & 2031

Figure 4. Sulfonylureas Product Picture

Figure 5. Metformin Product Picture

Figure 6. Thiazolidinediones Product Picture

Figure 7. Alpha-Glucosidase Inhibitors Product Picture

Figure 8. Global Oral Hypoglycemic Agents (OHAs) Market Value by Application (2020-2031) & (US$ Million)

Figure 9. Global Oral Hypoglycemic Agents (OHAs) Market Share by Application: 2024 & 2031

Figure 10. Type 2 Diabetes Mellitus

Figure 11. Type 1 Diabetes Mellitus

Figure 12. Global Oral Hypoglycemic Agents (OHAs) Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Oral Hypoglycemic Agents (OHAs) Market Size (2020-2031) & (US$ Million)

Figure 14. Global Oral Hypoglycemic Agents (OHAs) Sales (2020-2031) & (K Units)

Figure 15. Global Oral Hypoglycemic Agents (OHAs) Average Price (USD/Unit) & (2020-2031)

Figure 16. Oral Hypoglycemic Agents (OHAs) Report Years Considered

Figure 17. Oral Hypoglycemic Agents (OHAs) Sales Share by Manufacturers in 2024

Figure 18. Global Oral Hypoglycemic Agents (OHAs) Revenue Share by Manufacturers in 2024

Figure 19. Global 5 and 10 Largest Oral Hypoglycemic Agents (OHAs) Players: Market Share by Revenue in Oral Hypoglycemic Agents (OHAs) in 2024

Figure 20. Oral Hypoglycemic Agents (OHAs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 21. Global Oral Hypoglycemic Agents (OHAs) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 22. North America Oral Hypoglycemic Agents (OHAs) Sales Market Share by Country (2020-2031)

Figure 23. North America Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Country (2020-2031)

Figure 24. U.S. Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Canada Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Europe Oral Hypoglycemic Agents (OHAs) Sales Market Share by Country (2020-2031)

Figure 27. Europe Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Country (2020-2031)

Figure 28. Germany Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. France Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. U.K. Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Italy Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Russia Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region (2020-2031)

Figure 34. Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region (2020-2031)

Figure 35. China Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Japan Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. South Korea Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. India Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Australia Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Taiwan Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Indonesia Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Thailand Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Malaysia Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Philippines Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Latin America Oral Hypoglycemic Agents (OHAs) Sales Market Share by Country (2020-2031)

Figure 46. Latin America Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Country (2020-2031)

Figure 47. Mexico Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Brazil Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Argentina Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales Market Share by Country (2020-2031)

Figure 51. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Country (2020-2031)

Figure 52. Turkey Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Saudi Arabia Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. UAE Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Global Sales Market Share of Oral Hypoglycemic Agents (OHAs) by Type (2020-2031)

Figure 56. Global Revenue Market Share of Oral Hypoglycemic Agents (OHAs) by Type (2020-2031)

Figure 57. Global Oral Hypoglycemic Agents (OHAs) Price (USD/Unit) by Type (2020-2031)

Figure 58. Global Sales Market Share of Oral Hypoglycemic Agents (OHAs) by Application (2020-2031)

Figure 59. Global Revenue Market Share of Oral Hypoglycemic Agents (OHAs) by Application (2020-2031)

Figure 60. Global Oral Hypoglycemic Agents (OHAs) Price (USD/Unit) by Application (2020-2031)

Figure 61. Oral Hypoglycemic Agents (OHAs) Value Chain

Figure 62. Channels of Distribution (Direct Vs Distribution)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions